Beso schreef op 14 juni 2021 10:05:
Info van Relief omtrent patent en India en situatie Biophore :
Dear XXXXX:
Thank you for your inquiry.
We at Relief are concerned about the dramatic COVID-19 situation in India. There is a major need for additional treatment options for patients with COVID-19 in that country, and we know that the Indian pharmaceutical industry is working on various potential therapies to address this acute situation. Relief was not involved in Biophore’s work on aviptadil. We await with interest the outcome of Biophore’s EUA submission for India.
Relief holds a patent covering potential formulations of RLF-100 in various markets around the world. However, this does not include India. Please note the following: Relief holds a patent covering potential formulations of RLF-100™ in the United States valid until at least July 2029, with extension opportunities up to five years as well as in the EU and Rest of World (Great Britain, Germany, Turkey, Spain, Switzerland, Netherlands, Denmark, Ireland, Austria, PRC and Mexico) valid until at least 2026, excluding extension opportunities comparable to the U.S. In part to further build the IP portfolio, Relief and AdVita Lifescience GmbH signed a binding term sheet in January 2021 for Relief to acquire all shares of AdVita. Relief will gain access to all AdVita assets including future pending IP rights that may cover RLF-100™ inhaled formulation specifications for the potential application of inhaled aviptadil in the treatment of lung diseases such as ARDS and pulmonary sarcoidosis.
Kind regards,
Relief Therapeutics